CA3067219A1 - Methods and intermediates for the preparation of bile acid derivatives - Google Patents

Methods and intermediates for the preparation of bile acid derivatives Download PDF

Info

Publication number
CA3067219A1
CA3067219A1 CA3067219A CA3067219A CA3067219A1 CA 3067219 A1 CA3067219 A1 CA 3067219A1 CA 3067219 A CA3067219 A CA 3067219A CA 3067219 A CA3067219 A CA 3067219A CA 3067219 A1 CA3067219 A1 CA 3067219A1
Authority
CA
Canada
Prior art keywords
compound
formula
reacting
halogen
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3067219A
Other languages
English (en)
French (fr)
Inventor
Roberto Pellicciari
Antimo GIOIELLO
Gabriel GAVIN
Ronald D. Lewis
Matthew Yanik
Myoung Goo Kim
Fred Ronald LEUSINK
Bartjan KONING
Thomas HENSEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intercept Pharmaceuticals Inc
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of CA3067219A1 publication Critical patent/CA3067219A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA3067219A 2017-06-23 2018-06-22 Methods and intermediates for the preparation of bile acid derivatives Pending CA3067219A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523937P 2017-06-23 2017-06-23
US62/523,937 2017-06-23
PCT/US2018/039148 WO2018237350A1 (en) 2017-06-23 2018-06-22 METHODS AND INTERMEDIATES FOR PREPARING BILARY ACID DERIVATIVES

Publications (1)

Publication Number Publication Date
CA3067219A1 true CA3067219A1 (en) 2018-12-27

Family

ID=64691408

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3067219A Pending CA3067219A1 (en) 2017-06-23 2018-06-22 Methods and intermediates for the preparation of bile acid derivatives

Country Status (10)

Country Link
US (2) US11066437B2 (enExample)
EP (1) EP3642217A4 (enExample)
JP (1) JP7224307B2 (enExample)
KR (2) KR102831293B1 (enExample)
CN (1) CN110945006A (enExample)
AU (1) AU2018288883B2 (enExample)
BR (1) BR112019027458A2 (enExample)
CA (1) CA3067219A1 (enExample)
IL (2) IL271343B2 (enExample)
WO (1) WO2018237350A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013036835A1 (en) 2011-09-08 2013-03-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
RS67266B1 (sr) 2013-03-13 2025-10-31 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
SMT202100476T1 (it) 2015-07-06 2021-09-14 Sage Therapeutics Inc Ossisteroli e metodi di uso degli stessi
JP6882996B2 (ja) 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
BR112018000129B1 (pt) 2015-07-06 2024-01-09 Sage Therapeutics, Inc Compostos oxiesteróis, seus usos e composição farmacêutica
TN2018000106A1 (en) * 2015-10-07 2019-10-04 Intercept Pharmaceuticals Inc Farnesoid x receptor modulators
SI3436022T1 (sl) 2016-04-01 2022-08-31 Sage Therapeutics, Inc. Oksisteroli in postopki za uporabo le-teh
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (es) 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
MX392270B (es) 2016-09-30 2025-03-24 Sage Therapeutics Inc Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
CN110267966B (zh) 2016-10-18 2022-07-08 萨奇治疗股份有限公司 氧甾醇及其使用方法
EP4105223B1 (en) 2016-10-18 2025-04-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
WO2021155167A1 (en) * 2020-01-31 2021-08-05 The Johns Hopkins University Bile acid-gcpii inhibitor conjugates to treat inflammatory diseases
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
US12215127B2 (en) 2020-04-17 2025-02-04 Cornell University Compositions and methods for profiling of gut microbiota-associated bile salt hydrolase (BSH) activity
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
CN112795615A (zh) * 2021-02-03 2021-05-14 湖南醇康医药科技有限公司 一种诱变菌种以及微生物发酵制备熊去氧胆酸的方法
WO2023288123A1 (en) * 2021-07-16 2023-01-19 Interecept Pharmaceuticals, Inc. Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid
CN114045239B (zh) * 2021-11-08 2023-09-29 浙江树人学院（浙江树人大学） 具有二甲基乙酰胺降解能力的泛养副球菌ybh-7及应用
AU2023257308A1 (en) * 2022-04-21 2024-10-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists
WO2024163640A2 (en) * 2023-02-01 2024-08-08 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation of bile acid derivatives

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2403683A (en) * 1942-04-25 1946-07-09 Relchstein Tadeus Compounds of the cyclopentanopolyhydrophenanthrene series and process of making same
US2554882A (en) 1943-02-04 1951-05-29 Reichstein Tadeus 3-hydroxy-11-ketoetiocholanic acid and its esters
US3277121A (en) 1964-05-04 1966-10-04 Canada Packers Ltd Conversion of delta11-steroids to 11-oxygenated steroids
DE3040634A1 (de) 1980-10-29 1982-05-27 Hoechst Ag, 6000 Frankfurt Verfahren zur herstellung von 3 (alpha) -hydroxy-5- (beta) -pregnan-11,20-dion
DE10113257C1 (de) 2001-03-19 2002-11-14 Inst Mikrotechnik Mainz Gmbh Elektrophoresevorrichtung und ihre Verwendung
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
HRP20180931T1 (hr) 2013-05-14 2018-10-05 Intercept Pharmaceuticals, Inc. 11-hidroksil-6-supstituirani-derivati žučnih kiselina i njihovi aminokiselinski konjugati kao modulatori receptora za farnezoid x
CA2966885A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
HK1244708A1 (zh) 2014-11-26 2018-08-17 英安塔制药有限公司 作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法
RU2017130466A (ru) 2015-02-11 2019-03-12 Энанта Фармасьютикалс, Инк. Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
NZ735126A (en) 2015-03-31 2022-10-28 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
BR112018002499A2 (pt) 2015-08-07 2018-09-18 Intercept Pharmaceuticals Inc método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica
TN2018000106A1 (en) 2015-10-07 2019-10-04 Intercept Pharmaceuticals Inc Farnesoid x receptor modulators
CN107973834A (zh) 2016-10-22 2018-05-01 合帕吉恩治疗公司 作为fxr/tgr5调节剂的胆酸衍生物
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof

Also Published As

Publication number Publication date
IL271343B1 (en) 2023-08-01
BR112019027458A2 (pt) 2020-07-07
KR20250109791A (ko) 2025-07-17
WO2018237350A1 (en) 2018-12-27
JP7224307B2 (ja) 2023-02-17
AU2018288883A1 (en) 2020-01-16
US11066437B2 (en) 2021-07-20
IL271343B2 (en) 2023-12-01
AU2018288883B2 (en) 2022-06-02
EP3642217A1 (en) 2020-04-29
US20220127302A1 (en) 2022-04-28
IL271343A (en) 2020-01-30
KR20200020877A (ko) 2020-02-26
KR102831293B1 (ko) 2025-07-08
US20180371009A1 (en) 2018-12-27
JP2020525426A (ja) 2020-08-27
IL304455A (en) 2023-09-01
EP3642217A4 (en) 2021-06-16
CN110945006A (zh) 2020-03-31

Similar Documents

Publication Publication Date Title
US11066437B2 (en) Methods and intermediates for the preparation of bile acid derivatives
US12291549B2 (en) Farnesoid X receptor modulators
CN110003301B (zh) 用于治疗和/或预防fxr和tgr5/gpbar1介导的疾病的胆烷衍生物
AU2016297821B2 (en) Methods for preparation of bile acids and derivatives thereof
KR102527821B1 (ko) 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드
JP2018528230A (ja) 胆汁酸誘導体の調製のための方法および中間体
Sepe et al. Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity
JP2020528920A (ja) 胆汁酸類を製造するための方法
EP3445370A1 (en) Methods for the preparation of obeticholic acid and derivatives thereof
US20130102580A1 (en) Compositions and methods related to deoxycholic acid and its polymorphs
WO2024163640A2 (en) Methods and intermediates for the preparation of bile acid derivatives
CN101508717B (zh) 抗结核化合物帕格甾醇的合成方法
WO2023288123A1 (en) Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid
Bunyathaworn et al. Synthesis and Cytotoxicity Studies of Polyhydroxysterols and Their Sulfate Analogs
HK1260503A1 (zh) 制备奥贝胆酸及其衍生物的方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230621

EEER Examination request

Effective date: 20230621